Gene · 2898
GRIK2: glutamate ionotropic receptor kainate type subunit 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. GRIK2: glutamate ionotropic receptor kainate type subunit 2. Genes, record 2898. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2898
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q13002 | Glutamate receptor ionotropic, kainate 2 | 908 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents55
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 47757 | Q13002 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 14292 | Q13002 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 6231 | Q13002 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1870 | Q13002 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 6546 | Q13002 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1870 | Q13002 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 6546 | Q13002 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 14292 | Q13002 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 29334 | Q13002 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 6231 | Q13002 | Espacenet |
1 to 10 of 55
See all 55 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| SELURAMPANEL | CHEMBL3545042 | Glutamate receptor ionotropic kainate antagonist | ANTAGONIST | ChEMBL |
| TEZAMPANEL | CHEMBL3989703 | Glutamate receptor ionotropic kainate antagonist | ANTAGONIST | ChEMBL |
| TEZAMPANEL ANHYDROUS | CHEMBL14935 | Glutamate receptor ionotropic kainate antagonist | ANTAGONIST | ChEMBL |
| TOPIRAMATE | CHEMBL220492 | Glutamate receptor ionotropic kainate antagonist | ANTAGONIST | ChEMBL |
Trials161
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07588750 | TOPIRAMATE | ClinicalTrials.gov | ||
| NCT07384624 | TOPIRAMATE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06347497 | TOPIRAMATE | PHASE3 | ClinicalTrials.gov | |
| NCT06299891 | TOPIRAMATE | PHASE2 | ClinicalTrials.gov | |
| NCT06248931 | TOPIRAMATE | PHASE3 | ClinicalTrials.gov | |
| NCT06243692 | TOPIRAMATE | PHASE3 | ClinicalTrials.gov | |
| NCT05958160 | TOPIRAMATE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT05756764 | TOPIRAMATE | ClinicalTrials.gov | ||
| NCT05748483 | TOPIRAMATE | PHASE3 | ClinicalTrials.gov | |
| NCT05403229 | TOPIRAMATE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 161
See all 161 trialsNIH grants1,337
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | GRIK2 papers | Newest fiscal year |
|---|---|---|---|
| ZIAMH002857 | Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect | 8 | 2025 |
| R01CA206573 | Structure and function of Transient Receptor Potential Channels | 7 | 2025 |
| R01NS107253 | Single-Particle Cryo-EM Characterization of AMPA Receptor Functional States | 7 | 2025 |
| R35GM122528 | Dynamics Of Ligand Gated Ion Channels | 5 | 2025 |
| ZIAMH002844 | Genetic Determinants of Antidepressant Response | 5 | 2025 |
| R01AR078814 | Structural and functional principles of activation and regulation of the transient receptor potential channel TRPV3. | 4 | 2025 |
| U10AA008401 | Collaborative Study on the Genetics of Alcoholism (COGA). | 4 | 2025 |
| ZIAMH002927 | Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders | 4 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 3 | 2025 |
1 to 10 of 1,337Source NIH's project files
See all 1,337 nih grantsPapers1,523
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Design and Evaluation of Selective Positive Allosteric Modulators Targeting Kainate Receptors. | ACS Omega | 2026 | 42798915 | PubTator, text mining | PubMed |
| Recovery of Dysarthria in Anti-GluK2 Antibody-Associated Autoimmune Cerebellar Ataxia: A Longitudinal Acoustic and Perceptual Case Report. | Folia Phoniatr Logop | 2026 | 42789473 | PubTator, text mining | PubMed |
| Cryo-EM structures of apo, agonist- and antagonist-bound heteromeric kainate receptors. | Sci Adv | 2026 | 42536757 | PubTator, text mining | PubMed |
| Glutamate Ionotropic Kainate Receptors as Therapeutic Targets in Enzalutamide-Resistant and Neuroendocrine Prostate Cancer. | Int J Mol Sci | 2026 | 42450213 | PubTator, text mining | PubMed |
| GRIK2 drives LUAD progression via the cAMP/PKA/CREB pathway. | Tissue Cell | 2026 | 42184490 | PubTator, text mining | PubMed |
| Network pharmacology and molecular docking of arctic Pseudogymnoascus australis compounds targeting ionotropic glutamate receptors for neuroprotection. | Comput Biol Chem | 2026 | 42160907 | PubTator, text mining | PubMed |
| Mapping the multi-domain allosteric network for CKAMP44 modulation of AMPA receptors. | J Biol Chem | 2026 | 42107640 | PubTator, text mining | PubMed |
| Structures of partially occupied hetero-tetramers provide insight into kainate receptor activation and desensitization. | Nat Commun | 2026 | 42031800 | PubTator, text mining | PubMed |
| Trisomy 21 Drives ADARB1 Overexpression and Premature RNA Recoding in the Developing Fetal Brain. | Nat Commun | 2026 | 41917044 | PubTator, text mining | PubMed |
| Coexistence of anti-GluK2 and anti-LGI1 antibodies in a patient with autoimmune encephalitis: a rare case report and literature review. | BMC Neurol | 2026 | 41913114 | PubTator, text mining | PubMed |
1 to 10 of 1,523
See all 1,523 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2898
GET https://conductscience.org/api/genes/v1/2898/patents?page=2